Login to Your Account

Clinic Roundup

Tuesday, September 25, 2012
• Cell Therapeutics Inc., of Seattle, said data on their Phase I study of its oral JAK2 inhibitor pacritinib, or SB1518, showed encouraging anti-tumor activity and good tolerability in 34 patients with relapsed/refractory lymphoma.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription